Adaptive Radiotherapy for High-risk Prostate Cancer Using Multiparametric MRI (ARPC-MRI)

Adaptive Radiotherapy for High-risk Prostate Cancer Using Multiparametric MRI (ARPC-MRI) - a Feasibility Study

This small study will investigate the feasibility of using multi-parametric MRI to introduce and support adaptive radiotherapy treatments for high-risk prostate cancer.

Study Overview

• Status: Completed
• Conditions: Prostate Cancer

Detailed Description

Mount Vernon Cancer Centre at East and North Hertfordshire NHS Trust offers patients with certain cancers a treatment called adaptive radiotherapy. The aim of adaptive radiotherapy is to respond to physical changes that occur during treatment to ensure the radiation continues to be directed at the cancer and to minimise the amount of healthy tissue treated. For example, if tumour shrinkage or weight loss occurs during head and neck radiotherapy the patient may have a repeat CT scan and a new radiotherapy treatment plan after a few weeks of treatment. For patients with cancer of the bladder or cervix changes in bladder and uterus size and position can be predicted allowing the prospective creation of three radiotherapy treatment plans, each day the best fitting plan, i.e. the one that closely covers the tumour whilst giving minimal dose to normal tissues, is selected and used for treatment, this is known as plan-of-the-day adaptive radiotherapy.

Small changes in shape and position of the prostate occur but are generally the result of rectal changes which cannot be predicted, consequently adaptive radiotherapy based on physical change is not possible for prostate cancer treatments. However, recent literature suggests that magnetic resonance imaging (MRI) can detect changes within the prostate in response to radiotherapy, some studies have seen changes as early as the second week of radiotherapy treatment. A feasibility study to investigate if these changes can support radiotherapy treatment plan adaption for prostate cancer treatments is proposed, whether the plan can be adapted to give a higher treatment dose to any areas of the prostate that show poor response to radiotherapy without increasing bowel and bladder dose is of particular interest. The treatment for patients who participate in the study would not be changed but the results may help to personalise and improve the treatment of future patients.

• Study Type: Observational
• Enrollment (Actual): 5

Contacts and Locations

Study Locations

• United Kingdom
  • Middlesex
    • Northwood, Middlesex, United Kingdom, HA6 2RN
      • East and North Hertfordshire NHS Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

15 male patients scheduled to receive androgen deprivation therapy and external beam radiotherapy for high-risk prostate cancer at Mount Vernon Cancer Centre.

Description

Inclusion Criteria:

1. New diagnosis of high-risk prostate cancer: any of:

   1. Gleason score of 8, 9 or 10
   2. PSA > 20
   3. T3/4
2. Patient due to receive androgen deprivation therapy (ADT)
3. Prescribed 78Gy/39# external beam radiotherapy
4. Measurable dominant intraprostatic tumour on diagnostic imaging of at least 10mm diameter
5. ≥18 years of age
6. ECOG performance status of 0-1
7. Informed, written and witnessed consent to participate is required.

Exclusion Criteria:

1. Patients who are not due to receive androgen deprivation therapy (ADT)
2. Any contraindication to MRI scanning including contraindication to MRI contrast agents
3. Previous radiotherapy to the pelvis
4. Any physical or social reasons that would make attendance for additional visits impossible.
5. Any patient with or planned for prostate fiducial markers.
6. Unable to give informed consent.
7. Patients currently enrolled in an interventional clinical trial.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reproducability of DW-MRI	Apparent diffusion coefficient (ADC)	7 months
Reproducibility of DCE-MRI	Using volume transfer constant	7 months
Reproducibility of DCE-MRI	Using leakage space as a percentage of unit volume	7 months
Reproducibility of DCE-MRI	Using rate constant	7 months
MP-MRI Response Correlation	Developing methods to identify and delineate areas of tumour according to their response to radiotherapy treatment by correlating MP-MRI kinetic parameters with anatomical T2 MRI images	7 months
Assessment of adapted dosimetry	Amount of acceptable radiotherapeutic dose	After week 3 of radiotherapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of cell kill	Proportion of cells killed at given dose following androgen deprivation therapy	3 months
Tumour response prediction	Assess which proportion of tumours demonstrate areas of poor response that could benefit from adaptive radiotherapy	7 months

Collaborators and Investigators

• Sponsor: East and North Hertfordshire NHS Trust

Study record dates

Study Major Dates

• Study Start (Actual): February 5, 2019
• Primary Completion (Actual): September 1, 2024
• Study Completion (Actual): September 1, 2024

Study Registration Dates

• First Submitted: May 22, 2019
• First Submitted That Met QC Criteria: May 28, 2019
• First Posted (Actual): May 30, 2019

Study Record Updates

• Last Update Posted (Estimated): September 3, 2025
• Last Update Submitted That Met QC Criteria: September 1, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Prostatic Neoplasms
• Other Study ID Numbers: RD2018-46

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No